Reportlinker Adds UCB S.A.: PharmaVitae Profile

NEW YORK, Jan. 13, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

UCB S.A.: PharmaVitae Profile

http://www.reportlinker.com/p0177525/UCB-SA-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for UCB in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits

* Gain insight into UCB's strategic outlook across the next 6 years* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

Strategic insight into the prospects for UCB over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered

* Benchmark UCB's performance against key rivals in the prescription pharmaceutical sector* Examine the long-term sales potential of the monoclonal antibody Cimzia; providing a route to diversify its molecule type and therapy area offering

To order this report:

UCB S.A.: PharmaVitae Profile

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker